ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,28%
Bitcoin
60.687,49
-3,74%
Brent Oil
82,585
-1,63%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Innoviva Inc (INVA)

  7. Innoviva Inc (INVA) Notícias

INVA

Innoviva (INVA)

Innoviva Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:INVA
DataHoraFonteTítuloCódigoCompanhia
08/05/202417:46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INVAInnoviva Inc
08/05/202417:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVAInnoviva Inc
08/05/202417:05Business WireInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
08/05/202408:00Business WireInnoviva to Participate in the BofA Securities Health Care ConferenceNASDAQ:INVAInnoviva Inc
24/04/202408:00Business WireInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024NASDAQ:INVAInnoviva Inc
07/03/202421:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
29/02/202419:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INVAInnoviva Inc
29/02/202418:05Business WireInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
14/02/202409:23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INVAInnoviva Inc
10/01/202422:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
01/11/202317:15Business WireInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
01/11/202317:05Business WirePositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaNASDAQ:INVAInnoviva Inc
19/09/202309:30Business WireInnoviva to Participate in the Cantor Global Healthcare ConferenceNASDAQ:INVAInnoviva Inc
18/09/202309:00Business WireXACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsNASDAQ:INVAInnoviva Inc
25/08/202317:52Business WireInnoviva Appoints Stephen Basso as Chief Financial OfficerNASDAQ:INVAInnoviva Inc
02/08/202317:05Business WireInnoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
21/06/202307:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INVAInnoviva Inc
06/06/202317:05Business WireInnoviva to Participate in the Goldman Sachs Annual Global Healthcare ConferenceNASDAQ:INVAInnoviva Inc
24/05/202307:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INVAInnoviva Inc
23/05/202320:10Dow Jones NewsFDA Approves Innoviva's Bacterial Pneumonia TreatmentNASDAQ:INVAInnoviva Inc
23/05/202319:42Business WireInnoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous UseNASDAQ:INVAInnoviva Inc
17/05/202318:19Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:INVAInnoviva Inc
15/05/202318:19Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:INVAInnoviva Inc
11/05/202319:45Business WireResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious DiseasesNASDAQ:INVAInnoviva Inc
09/05/202318:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:INVAInnoviva Inc
09/05/202317:32Business WireInnoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
28/04/202318:30Business WireInnoviva Announces Retirement of Board ChairmanNASDAQ:INVAInnoviva Inc
28/04/202318:05Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:INVAInnoviva Inc
28/04/202318:05Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:INVAInnoviva Inc
17/04/202317:31Business WireSulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory CommitteeNASDAQ:INVAInnoviva Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:INVA

Seu Histórico Recente

EU
X639S
X639S
LSE
MI11
HITB
EKOBTC
EchoLink
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados